Osteo Science Foundation Launched
Osteo Science Foundation
October 28, 2013
In October 2013, Dr Peter Geistlich, the President of the Board of Directors of Geistlich Pharma AG, together with Geistlich Pharma AG in the USA, launched the Osteo Science Foundation which has its registered office in Philadelphia. The goal of the Foundation is to support and promote independent research in North America in oral and maxillofacial surgery and to put its results from theory into practice.
The Osteo Science Foundation launched by Dr Peter Geistlich has been operational since October. The Foundation with its registered office in Philadelphia has made it its goal to establish a platform in order to support independent basic and applied research and to develop new therapy approaches and clinical treatment methods in oral and maxillofacial surgery (OMF). The theory of conveying new knowledge is also a pivotal task of the new organisation.
Late honour for the pioneer Dr Philip Boyne
This foundation was established to honour the surgical excellence and outstanding research of Dr Boyne and to make his vision of bone and tissue regeneration reality. Dr Boyne died in June 2008. He was a world-renowned oral and maxillofacial surgeon, implantologist, biological innovator and bone physiologist. He was also a very good friend of Dr Peter Geistlich. Philip Boyne and Peter Geistlich did pioneering work in bone regeneration. Together, the two of them succeeded in the 1980s in freeing bone material from organic components for the first time, without changing the natural microstructure and bone composition. The pioneers jointly developed the bone replacement material Geistlich Bio-Oss®, which revolutionised regenerative dental medicine.
Luminaries on the Foundation Board
The management of the Foundation comprises highly respected, scientific experts from the fields of oral and maxillofacial surgery: Jay P. Malmquist is a maxillofacial surgeon with great experience in implantology, bone regeneration and development. Alan S. Herford is the President and Programme Director of Oral and Maxillofacial Surgery at the Faculty of Dental Medicine at the University of Loma Linda. Peter K. Moy is a clinical professor for oral and maxillofacial surgery in the Department of Diagnostic & Surgical Sciences at the Faculty of Dental Medicine at the UCLA. Greg Bosch, CEO of Geistlich Pharma North America, the American Geistlich Pharma affiliate, represents industry. Andrea Boldman is the Executive Director of the Foundation. She is a strong advocate of medical research and shares the Foundation Board's goal to provide financial assistance for excellent research into oral and maxillofacial surgery.
Contact: Dr. Mirjam Kessler, Director Corporate Communications, Geistlich Pharma AG
Tel. +41 41 492 56 29, Mobile: +41 79 775 94 12, E-Mail: email@example.com